Short Interest in CalciMedica, Inc. (NASDAQ:CALC) Decreases By 6.6%

CalciMedica, Inc. (NASDAQ:CALC) was the recipient of a significant drop in short interest in January. As of January 15th, there was short interest totalling 61,300 shares, a drop of 6.6% from the December 31st total of 65,600 shares. Based on an average daily trading volume, of 59,400 shares, the short-interest ratio is presently 1.0 days. Approximately 0.9% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of CalciMedica in a research report on Thursday, November 14th.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in CALC. PVG Asset Management Corp acquired a new stake in shares of CalciMedica during the 3rd quarter worth about $67,000. Atria Investments Inc grew its position in CalciMedica by 136.5% during the 3rd quarter. Atria Investments Inc now owns 26,503 shares of the company’s stock worth $117,000 after acquiring an additional 15,296 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of CalciMedica by 51.2% in the third quarter. Geode Capital Management LLC now owns 66,553 shares of the company’s stock valued at $295,000 after buying an additional 22,525 shares in the last quarter.

CalciMedica Trading Up 3.1 %

CALC traded up $0.08 during trading on Monday, hitting $2.64. The stock had a trading volume of 132,582 shares, compared to its average volume of 28,456. CalciMedica has a 12 month low of $2.05 and a 12 month high of $6.26. The company has a 50 day simple moving average of $2.99 and a 200-day simple moving average of $3.72. The firm has a market cap of $35.59 million, a PE ratio of -2.44 and a beta of 1.22.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.